Nymox Pharmaceutical has reported that the company's new updated safety committee review of safety data for its ongoing multi-center U.S. Phase II trial of NX-1207 has revealed no serious drug side effects. The entire cohort of enrolled subjects have now all completed their drug dosing in the trial. NX-1207 is Nymox's lead drug candidate for the treatment of benign prostatic hyperplasia (BPH).

NX-1207 has completed two earlier Phase I and II trials where the drug produced on average over 23 percent prostate shrinkage in one month with minimal side effects. Overall there have been no sexual side effects, and a better side effect profile compared to existing drugs. The symptomatic improvement in earlier trials reached 10 points on the BPH Symptom Score.